Key statistics dashboard for Dare Bioscience, Inc. (DARE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Stock Data
| Price | $0.73 |
| Market Cap | $11M |
| Enterprise Value | $5.0M |
| Beta | 0.90 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.92 |
| Price / Book | -19.29 |
| P/S | 7.96 |
| EV/EBITDA | -0.55 |
| EV/Sales | 3.67 |
| EV/FCF | -0.43 |
| P/FCF | -0.92 |
| Earnings Yield | -101.71% |
| FCF Yield | -108.17% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -89.45% |
| EBIT Margin | -787.60% |
| EBITDA Margin | -672.59% |
| Operating Margin | -813.38% |
| Net Margin | -804.37% |
| Return on Equity | -748.08% |
| Return on Assets | -49.12% |
| Return on Invested Capital | -179.10% |
| Return on Capital Employed | -203.95% |
Financial Health
| Current Ratio | 0.99 |
| Quick Ratio | 0.99 |
| Cash Ratio | 0.75 |
| Debt / Equity | -12.08 |
| Debt / Assets | 30.24% |
| Net Debt / EBITDA | 0.64 |
| Interest Coverage | -55.72 |
Per-Share Data
| Revenue per share | 0.09 |
| Book Value per share | -0.04 |
| Cash per share | 0.85 |
| FCF per share | -0.79 |
| Tangible Book Value per share | -0.04 |
| Dividend per share | 0.00 |
Related companies: ADTX · AIMD · ANL · ASBP · ATHA · CTXR · FBLG
Explore sector: Healthcare · Biotechnology
More sections of DARE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks